Company profile: Reach Separations
1.1 - Company Overview
Company description
- Provider of chiral and achiral separation services, discovery chromatography, large-scale SFC, impurity isolations, and analytical services, including EE determinations; purification of hundreds of grams of racemate using preparative HPLC/SFC and large-scale SFC with automated screening and evaporation; LC-MS/SFC-MS method development, orthogonal purity analysis, multi-component resolutions, reference standard generation; MS-MS/NMR elucidation; QC purity checks and stability studies.
Products and services
- Large Scale SFC for Chiral Purification: Conducts industrial-scale chiral purification, processing hundreds of grams of racemate per week with large-scale SFC instrumentation and integrated automated evaporation capabilities for efficient throughput
- Discovery Chromatography: Delivers analytical-grade project support from method development for reaction monitoring and purity assessments to separating racemates and achiral mixtures, leveraging SFC for challenging purifications
- Impurity Isolations: Produces research-grade pure samples of unknown impurities, supplying minor components from crude samples and furnishing elucidation packages with MS-MS and NMR data for detailed characterization
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Reach Separations
Elegen
HQ: United States
Website
- Description: Provider of cell-free DNA synthesis solutions, including ENFINIA DNA producing long, complex linear DNA up to 7kb with 99.999% per-base accuracy, shipped in 6 to 8 business days; high-complexity DNA synthesis for challenging sequences like long repeats and GC-rich regions, with delivery as fast as 10 business days; and an Early Access Program for pre-commercial products, including sequences longer than 15,000 base pairs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elegen company profile →
InVitro International
HQ: United States
Website
- Description: Provider of proprietary non-animal testing alternatives, with a pioneering focus on their development and application.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InVitro International company profile →
ONI
HQ: United Kingdom
Website
- Description: Provider of super-resolution microscopy solutions, making this advanced technology accessible to new generations of researchers. Offers the Nanoimager, the world's first benchtop-sized super-resolution microscope, delivering a step change in usability and precision, together with next-generation consumable products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ONI company profile →
TetraVitae Bioscience
HQ: United States
Website
- Description: Provider of biobased chemicals, plastics, and fuels designed to replace petroleum-derived products, leveraging proprietary technology in industrial fermentations, process engineering, microbiology, and cellulosic feedstocks to lower production costs and enable competitive alternatives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TetraVitae Bioscience company profile →
NanoCellect Biomedical
HQ: United States
Website
- Description: Provider of microfluidic cell analysis and sorting solutions, including WOLF G2 benchtop cell sorter with two lasers and up to nine colors for gentle bulk or single-cell workflows; VERLO image-guided sorter combining flow cytometry with image analysis for complex samples; N1 single-cell dispenser for 96-/384-well plates; CS1 chiller-stirrer for temperature control; and disposable, sterile microfluidic cartridges without cross-contamination.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoCellect Biomedical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Reach Separations
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Reach Separations
2.2 - Growth funds investing in similar companies to Reach Separations
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Reach Separations
4.2 - Public trading comparable groups for Reach Separations
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →